€7 for visa free travel: EU changes entry rules - 112 International
€7 for visa free travel: EU changes entry rules - 112 International |
- €7 for visa free travel: EU changes entry rules - 112 International
- Minestrone soup could help fight against malaria, study says - KUTV 2News
- Snap Up These 5 Stocks With High Earnings Yield - Nasdaq
€7 for visa free travel: EU changes entry rules - 112 International Posted: 16 Jan 2020 08:37 AM PST From January 1, 2021, the European Union will launch an additional security measure, an automatic ETIAS system, designed to screen out travelers who may be a threat to the EU and to fight against illegal migration. Now, all citizens of countries that have obtained visa-free entry agreements with Schengen (including Ukrainians) will have to apply for it. Some Ukrainians think that ETIAS is a kind of analogue to the visa system, which will abolish visa free travels to the EU, but it is not so. What is ETIAS? ETIAS stands for the European Travel Information and Authorisation System. It was announced by the European Commission in November 2016 and was implemented into legislation in September 2018. The intention of forming the system was to improve the security of EU member states within the Schengen region by capturing data on travellers that currently visit the area without a visa. The ETIAS will only pre-screen travellers not needing a Schengen Visa. The screening would pertain to terrorism or migration related risks. The objective is to identify individuals who pose security threats before they are able to travel to the Schengen area. ETIAS is not a visa, it is a visa waiver, similar to the U.S. ESTA and Canadian eTA. Travelers currently visiting European Member countries visa-free, will require an ETIAS from 2021 onwards. Passport holders of the EU single market are exempt from ETIAS It is noteworthy that not only Ukrainians will have to pass the new authorization, but also to citizens of other countries with a Schengen visa-free regime, including the USA, Canada, Australia and Japan. The full list of countries is available on the official ETIAS website. Schengen visa holders are exempt from ETIAS authorization. How to apply for ETIAS? Authorization will be necessary for everyone, regardless of purpose of visit or age. You must apply for an authorization no later than 96 hours before your trip. The procedure will be done online using the official website or mobile application. Applying for an ETIAS will require a passport along with a computer or mobile device having internet connection as well as a valid form of payment. We approximate the application will take 20 minutes to complete yet this could vary depending on the number of additional fields you may be required to fill-out. You will not need to apply for an ETIAS until January 1, 2021. Applicants will need to provide the following information as part of their ETIAS application:
The ETIAS application fee is €7, however, travellers under the age of 18 or over the age of 70 will not need to pay the fee. Debit and credit card payments are accepted. Upon payment of the fee, paid by applicants between the ages of 18 to 70, the ETIAS application will be processed and a decision will be obtained within minutes. Checks and results An ETIAS application is automatically processed based on the following three factors:
The applicant identify, travel document and background questions are then checked against Schengen Information System (SIS), Visa Information System (VIS), EUROPOL DATA, e Interpol Stolen and Lost Travel Document database (SLTD) and the Interpol Travel Documents Associated with Notices database (TDAWN), EURODAC and others, in addition to the ETIAS Central Unit's own screening rules and watchlist. A positive match detected by the automated processing system that deems the applicant as a possible security or migration risk, it will result in the ETIAS application being manually processed. Manual processing is performed by the ETIAS Central Unit and ETIAS National Units where relevant. If additional information is required from the applicant, they will be contacted within days of receiving notification that their ETIAS requires additional processing. The ETIAS system will provide all applicants notification of their "approved", "refused" or "manual processing" ETIAS status within 96 hours of application submission. Completing your online application form will take less than 10 minutes. After submission, your ETIAS application will be processed instantly and you will receive a decision from the system within 96 hours or less. A small percentage of applications may take up to four weeks to process if additional documentation is required from the applicant. If your ETIAS has not yet been approved and you do not have any other travel authorization, you will not be able to enter a country within the European Union. The ETIAS will be valid for three years, or the date of passport expiry (whichever comes first), and can be used for stays of up to 90 days in a 180 day period. If you are not eligible for ETIAS or your ETIAS application is denied, you need to most likely apply for a Schengen visa to visit Europe. If you wish to stay in the EU longer then the amount of time granted under the ETIAS, you will need to switch to the relevant visa category based on the purposes of your stay. |
Minestrone soup could help fight against malaria, study says - KUTV 2News Posted: 28 Dec 2019 12:00 AM PST [unable to retrieve full-text content]Minestrone soup could help fight against malaria, study says KUTV 2News |
Snap Up These 5 Stocks With High Earnings Yield - Nasdaq Posted: 15 Jan 2020 07:01 AM PST Earnings yield is useful for investors concerned about the rate of return on an investment. This metric, expressed in percentage, is calculated as annual earnings per share (EPS) divided by market price per share — the inverse of the price-to-earnings (P/E) ratio. While comparing stocks, if other factors are similar, the one with higher earnings yield is considered undervalued. That's because this metric measures the anticipated yield (or return) from earnings for each dollar invested in a stock today. Earnings yield is not as widely used as P/E ratio as a valuation metric but investors most commonly compare the earnings yield of a stock to the prevailing interest rates, such as the current 10-year Treasury yield, to get a sense of the return on investment it offers compared to virtually risk-free returns. If the yield on the stock is lower than the 10-year Treasury yield, the stock would be considered overvalued relative to bonds. Conversely, if the yield on the stock is higher, it would be considered undervalued. The Winning Strategy We have set Earnings Yield greater than 10% as our primary screening criterion but it alone cannot be used for picking stocks that have the potential to generate solid returns. So, we have added the following parameters to the screen: Estimated EPS growth for the next 12 months greater than or equal to the S&P 500: This metric compares the 12-month forward EPS estimate with the 12-month actual EPS. Average Daily Volume (20 Day) greater than or equal to 100,000: High trading volume implies that a stock has adequate liquidity. Current Price greater than or equal to $5. Buy-Rated Stocks: Stocks with a Zacks Rank #1 (Strong Buy) or 2 (Buy) have been known to outperform peers in any type of market environment. You can see the complete list of today's Zacks #1 Rank stocks here. Our Choices Here are five of the 60 stocks that made it through the screen: Genesco Inc. GCO: Nashville-based specialty retailer, Genesco sells footwear, headwear and accessories in retail stores in the United States and Canada.It sports a Zacks Rank #1 and has an expected EPS growth rate of 5% for the next 3-5 years. GreenTree Hospitality Group Ltd. GHG: China-based GreenTree operates as a franchised hotel operator. It operates business chain hotels, serviced apartments, shell inns and hostels. It sports a Zacks Rank #1 and has an expected EPS growth rate of 17.6% for the next 3-5 years. Bristol-Myers Squibb Company BMY: New York-based Bristol-Myers is a global specialty biopharmaceutical company focused on the development of treatments targeting serious diseases. It carries a Zacks Rank #2 and has an expected EPS growth rate of 13.4% for the next 3-5 years. Barclays PLC BCS: Headquartered in London, Barclays is a major global banking and financial services company. It carries a Zacks Rank #1 and has an expected EPS growth rate of 2.8% for the next 3-5 years. Valero Energy Corporation VLO: San Antonio, TX-based Valero Energy Corporation is the largest independent refiner and marketer of petroleum products in the world. It carries a Zacks Rank #2 and has an expected EPS growth rate of 8% for the next 3-5 years. You can get the rest of the stocks on this list by signing up now for a 2-week free trial to the Research Wizard stock picking and backtesting software. You can also create your own strategies and test them first before making investments. The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out. Click here to sign up for a free trial to the Research Wizard today. Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. Disclosure: Performance information for Zacks' portfolios and strategies are available at: https://www.zacks.com/performance. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Barclays PLC (BCS): Free Stock Analysis Report Valero Energy Corporation (VLO): Free Stock Analysis Report Genesco Inc. (GCO): Free Stock Analysis Report GreenTree Hospitality Group Ltd. Sponsored ADR (GHG): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
You are subscribed to email updates from "parasitic diseases list" - Google News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States |
Comments
Post a Comment